| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 14224 | 2012 |
| Safety and activity of anti–PD-L1 antibody in patients with advanced cancer JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ... New England Journal of Medicine 366 (26), 2455-2465, 2012 | 9064 | 2012 |
| Immune checkpoint blockade: a common denominator approach to cancer therapy SL Topalian, CG Drake, DM Pardoll Cancer cell 27 (4), 450-461, 2015 | 4244 | 2015 |
| Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ... Journal of clinical oncology 28 (19), 3167-3175, 2010 | 3665 | 2010 |
| A draft map of the human proteome MS Kim, SM Pinto, D Getnet, RS Nirujogi, SS Manda, R Chaerkady, ... Nature 509 (7502), 575-581, 2014 | 2529 | 2014 |
| Inflammation in prostate carcinogenesis AM De Marzo, EA Platz, S Sutcliffe, J Xu, H Grönberg, CG Drake, Y Nakai, ... Nature Reviews Cancer 7 (4), 256-269, 2007 | 2103 | 2007 |
| Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape SR Woo, ME Turnis, MV Goldberg, J Bankoti, M Selby, CJ Nirschl, ... Cancer research 72 (4), 917-927, 2012 | 1830 | 2012 |
| Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity SL Topalian, CG Drake, DM Pardoll Current opinion in immunology 24 (2), 207-212, 2012 | 1713 | 2012 |
| Role of LAG-3 in regulatory T cells CT Huang, CJ Workman, D Flies, X Pan, AL Marson, G Zhou, EL Hipkiss, ... Immunity 21 (4), 503-513, 2004 | 1647 | 2004 |
| Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a … ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ... The lancet oncology 15 (7), 700-712, 2014 | 1623 | 2014 |
| Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma D Miao, CA Margolis, W Gao, MH Voss, W Li, DJ Martini, C Norton, ... Science 359 (6377), 801-806, 2018 | 1078 | 2018 |
| Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas J Zeng, AP See, J Phallen, CM Jackson, Z Belcaid, J Ruzevick, N Durham, ... International Journal of Radiation Oncology* Biology* Physics 86 (2), 343-349, 2013 | 1044 | 2013 |
| Mechanisms of immune evasion by tumors CG Drake, E Jaffee, DM Pardoll Advances in immunology 90, 51-81, 2006 | 895 | 2006 |
| LAG 3 (CD 223) as a cancer immunotherapy target LP Andrews, AE Marciscano, CG Drake, DAA Vignali Immunological reviews 276 (1), 80-96, 2017 | 894 | 2017 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 880* | 2018 |
| Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma S Lyford-Pike, S Peng, GD Young, JM Taube, WH Westra, B Akpeng, ... Cancer research 73 (6), 1733-1741, 2013 | 854 | 2013 |
| Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy AB Sharabi, M Lim, TL DeWeese, CG Drake The lancet oncology 16 (13), e498-e509, 2015 | 852 | 2015 |
| Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant … TM Beer, ED Kwon, CG Drake, K Fizazi, C Logothetis, G Gravis, V Ganju, ... Journal of Clinical Oncology 35 (1), 40-47, 2017 | 771 | 2017 |
| Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity TJ Harris, JF Grosso, HR Yen, H Xin, M Kortylewski, E Albesiano, ... The Journal of Immunology 179 (7), 4313-4317, 2007 | 738 | 2007 |
| Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ... Clinical Cancer Research 19 (2), 462-468, 2013 | 671 | 2013 |
Andrew PardollJohns Hopkins University school of medicine在 jhmi.edu 的电子邮件经过验证
